DNA X, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 64/100
What the filing says
DNA X, Inc. (market cap ~$12.6M) issued 1,346,531 shares of Series B Convertible Preferred Stock to DNA Holdings Venture, Inc. at $6.00/share for total proceeds of $8.079M ($5M cash + $3.079M note cancellation, dated June 29, 2026). Each preferred share converts 1:1 to common stock at $6.00/conversion price upon shareholder approval. DNA Holdings (holder >5% and board-affiliated via Scott Walker) receives registration rights and 50% pro-rata participation rights in future equity financings for 12 months. Company also grants 2.494M common shares to consultants (DNA Holdings, Scott Walker, Brock Pierce) upon shareholder approval.
Why this rating
Dilutive preferred issuance at ~64% of company's market cap raises working capital but requires shareholder approval; participation rights and consultant grants add future dilution. Material financing but company retains control; valuation neutral pending execution.
Extracted items
- 1.01 material agreement
- 5.03 charter/bylaw change
- 3.02
- 3.03
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.